Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 25242081)

  • 1. Epigallocatechin-3-gallate potentiates the effect of curcumin in inducing growth inhibition and apoptosis of resistant breast cancer cells.
    Wang S; Chen R; Zhong Z; Shi Z; Chen M; Wang Y
    Am J Chin Med; 2014; 42(5):1279-300. PubMed ID: 25242081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of multidrug resistant in cancer cells by EGCG, tannic acid and curcumin.
    Li H; Krstin S; Wink M
    Phytomedicine; 2018 Nov; 50():213-222. PubMed ID: 30466981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
    Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amphiphilic Copolymeric Micelles for Doxorubicin and Curcumin Co-Delivery to Reverse Multidrug Resistance in Breast Cancer.
    Lv L; Qiu K; Yu X; Chen C; Qin F; Shi Y; Ou J; Zhang T; Zhu H; Wu J; Liu C; Li G
    J Biomed Nanotechnol; 2016 May; 12(5):973-85. PubMed ID: 27305819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFκB signaling.
    Chung SS; Vadgama JV
    Anticancer Res; 2015 Jan; 35(1):39-46. PubMed ID: 25550533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A P-glycoprotein- and MRP1-independent doxorubicin-resistant variant of the MCF-7 breast cancer cell line with defects in caspase-6, -7, -8, -9 and -10 activation pathways.
    Park SJ; Wu CH; Safa AR
    Anticancer Res; 2004; 24(1):123-31. PubMed ID: 15015586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigallocatechin-3-gallate promotes apoptosis and reversal of multidrug resistance in esophageal cancer cells.
    Liu L; Ju Y; Wang J; Zhou R
    Pathol Res Pract; 2017 Oct; 213(10):1242-1250. PubMed ID: 28964574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigallocatechin gallate (EGCG) suppresses growth and tumorigenicity in breast cancer cells by downregulation of miR-25.
    Zan L; Chen Q; Zhang L; Li X
    Bioengineered; 2019 Dec; 10(1):374-382. PubMed ID: 31431131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
    Wang TX; Yang XH
    Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells.
    Farabegoli F; Papi A; Orlandi M
    Biosci Rep; 2011 Apr; 31(2):99-108. PubMed ID: 20446926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo reversal of doxorubicin resistance by (-)-epigallocatechin gallate in a solid human carcinoma xenograft.
    Zhang Q; Wei D; Liu J
    Cancer Lett; 2004 May; 208(2):179-86. PubMed ID: 15142676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Y6, an epigallocatechin gallate derivative, on reversing doxorubicin drug resistance in human hepatocellular carcinoma cells.
    Wen Y; Zhao RQ; Zhang YK; Gupta P; Fu LX; Tang AZ; Liu BM; Chen ZS; Yang DH; Liang G
    Oncotarget; 2017 May; 8(18):29760-29770. PubMed ID: 28423656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGCG down-regulates telomerase in human breast carcinoma MCF-7 cells, leading to suppression of cell viability and induction of apoptosis.
    Mittal A; Pate MS; Wylie RC; Tollefsbol TO; Katiyar SK
    Int J Oncol; 2004 Mar; 24(3):703-10. PubMed ID: 14767556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of c-fos by shRNA sensitizes adriamycin-resistant MCF-7/ADR cells to chemotherapeutic agents via P-glycoprotein inhibition and apoptosis augmentation.
    Shi R; Peng H; Yuan X; Zhang X; Zhang Y; Fan D; Liu X; Xiong D
    J Cell Biochem; 2013 Aug; 114(8):1890-900. PubMed ID: 23494858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigallocatechin-3 gallate induces growth inhibition and apoptosis in human breast cancer cells through survivin suppression.
    Tang Y; Zhao DY; Elliott S; Zhao W; Curiel TJ; Beckman BS; Burow ME
    Int J Oncol; 2007 Oct; 31(4):705-11. PubMed ID: 17786300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression.
    Wang S; Wang L; Chen M; Wang Y
    Chem Biol Interact; 2015 Jun; 235():76-84. PubMed ID: 25824409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergism from sequenced combinations of curcumin and epigallocatechin-3-gallate with cisplatin in the killing of human ovarian cancer cells.
    Yunos NM; Beale P; Yu JQ; Huq F
    Anticancer Res; 2011 Apr; 31(4):1131-40. PubMed ID: 21508356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of P-glycoprotein function and reversal of multidrug resistance by (-)-epigallocatechin gallate in human cancer cells.
    Qian F; Wei D; Zhang Q; Yang S
    Biomed Pharmacother; 2005 Apr; 59(3):64-9. PubMed ID: 15795098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced anticancer potency of doxorubicin in combination with curcumin in gastric adenocarcinoma.
    Firouzi Amoodizaj F; Baghaeifar S; Taheri E; Farhoudi Sefidan Jadid M; Safi M; Seyyed Sani N; Hajazimian S; Isazadeh A; Shanehbandi D
    J Biochem Mol Toxicol; 2020 Jun; 34(6):e22486. PubMed ID: 32128952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel and curcumin coadministration in novel cationic PEGylated niosomal formulations exhibit enhanced synergistic antitumor efficacy.
    Alemi A; Zavar Reza J; Haghiralsadat F; Zarei Jaliani H; Haghi Karamallah M; Hosseini SA; Haghi Karamallah S
    J Nanobiotechnology; 2018 Mar; 16(1):28. PubMed ID: 29571289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.